华蟾素胶囊联合肝动脉灌注化疗栓塞对肝癌患者血浆纤维蛋白原、肿瘤标志物浓度的影响

摘要

Objective To study the effects of cinobufotalin capsule combined with transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.Methods 68 patients with hepatocellular carcinoma from January,2013 to March,2016 were selected and divided into the combination group and chemotherapy group according to the random number table method,each with 34 cases.The combination group was treated with transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy embolization.The levels of D-dimer,tumor markers,clinical efficacy and quality of life scores were observed before and after treatment in 68 patients.Results There was no significant difference in plasma fibrinogen(FIB)in combination group before and after treatment.Before treatment,the levels of FIB)was similar to chemotherapy group.After treatment,the FIB content in the chemotherapy group was significantly higher than before treatment and that in the combination group the differences were statistically significant(P<0.05).After treatment,the levels of cytokeratin 19,carcinoembryonic antigen and neuron-specific enolase in two group were significantly higher than those before treatment(P<0.05).But there was no significant difference between the two groups after treatment.The rate of disease control in the combination group was significantly higher than that in the chemotherapy group(77.5％vs.65.4％,P<0.05).Cases of diarrhea and insomnia in chemotherapy group were similar to the combination group,but the differences of cases of pain and fatigue between two group were statistically significant(P<0.05).Conclusion Cinobufotalin capsule combined with transcatheter arterial chemoembolization can improve the hypercoagulability of the patient's blood,and is beneficial to the treatment of cancer,improve the disease control rate and improve the life of patients.%目的 探究华蟾素胶囊联合肝动脉灌注化疗栓塞对肝癌患者血浆纤维蛋白原、肿瘤标志物浓度的影响,以期探寻治疗肝癌患者的最佳方案.方法 选取2013年1月～2016年3月于武警浙江省总队嘉兴医院接受治疗的肝癌患者68例.按照随机数表法随机分为联合组和化疗组,各34例.联合组在肝动脉灌注化疗栓塞的基础上联合服用华蟾素胶囊,化疗组行肝动脉灌注化疗栓塞.观察68例患者治疗前后血浆纤维蛋白原(FIB)含量、肿瘤标志物浓度及其临床疗效、生活质量.结果 联合组治疗前后血浆纤维蛋白原(FIB)含量差异无统计学意义,治疗前联合组和化疗组FIB差异无统计学意义.但治疗后化疗组 FIB含量明显高于治疗前,也明显高于联合组,差异有统计学意义(P<0.05).治疗后,2组细胞角蛋白19片段、癌胚抗原、神经元特异性烯醇化酶浓度均明显高于治疗前(P<0.05).但2组治疗后各指标差异无统计学意义.联合组患者疾病控制率(77.5％)明显大于化疗组(65.4％),差异有统计学意义(P<0.05).联合组腹泻、失眠例数与化疗组差异无统计学意义;疼痛、疲倦例数明显少于于化疗组,差异有统计学意义( P <0.05).联合组腹泻、失眠例数与化疗组差异无统计学意义;疼痛、疲倦例数明显少于于化疗组,差异有统计学意义( P <0.05). 结论 华蟾素胶囊联合肝动脉灌注化疗栓塞能够改善肝癌患者血液的高凝状态,有利于肝癌的治疗,提升患者疾病控制率,改善患者生活,临床效果较好.